This Viewpoint discusses the value judgments that are always incorporated into payers’ and health systems’ assessments of the clinical- and cost-effectiveness of interventions and into their discussions whether to adopt them.
This recommendation statement from the Second Panel on Cost-Effectiveness in Health and Medicine reviews methodological advances in cost-effective analyses and updates the 1996 recommendations for the conduct and report of cost-effective analyses.
This study estimates the cost-effectiveness of adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy for patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD).
This Viewpoint describes the efforts of social enterpreneurs, individuals and organizations who develop self-sustaining business models to deliver cost-effective health care and social services to poor and underserved communities around the world.
This study compares the cost-effectiveness of using various 10-year atherosclerotic cardiovascular disease risk thresholds for initiating statin therapy.
This Special Communication reports the amount of financial assistance high-income countries and private organizations provide to developing countries for health, and their areas of focus.
This prospective economic evaluation reports that use of LMW heparin for venous thromboembolism prophylaxis in critically ill patients was more effective than unfractionated heparin, with similar or lower costs.